Agency

Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 10, Status: Authorised

Retrieved on: 
Friday, January 5, 2024

Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 10, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 16, Status: Authorised

Retrieved on: 
Friday, January 5, 2024

Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 16, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Retrieved on: 
Friday, January 5, 2024

Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Praluent, alirocumab, Date of authorisation: 23/09/2015, Revision: 21, Status: Authorised

Retrieved on: 
Friday, January 5, 2024

Human medicines European public assessment report (EPAR): Praluent, alirocumab, Date of authorisation: 23/09/2015, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Praluent, alirocumab, Date of authorisation: 23/09/2015, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Agamree, Vamorolone, Date of authorisation: 14/12/2023, Status: Authorised

Retrieved on: 
Friday, January 5, 2024

Human medicines European public assessment report (EPAR): Agamree, Vamorolone, Date of authorisation: 14/12/2023, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Agamree, Vamorolone, Date of authorisation: 14/12/2023, Status: Authorised

Glytec Announces Patrick F. Cua as Chief Executive Officer

Retrieved on: 
Thursday, January 4, 2024

WALTHAM, Mass., Jan. 4, 2024 /PRNewswire/ -- Glytec, the only provider of cloud-based insulin management software as a service (SaaS) solutions across the continuum of care, today announced the appointment of Patrick F. Cua as Chief Executive Officer. In his new role, Cua will prepare the company for rapid growth to meet increasing demand for Glucommander amid a surging industry focus on healthcare outcomes, cost savings, diabetes technology, and glycemic management.

Key Points: 
  • WALTHAM, Mass., Jan. 4, 2024 /PRNewswire/ -- Glytec , the only provider of cloud-based insulin management software as a service (SaaS) solutions across the continuum of care, today announced the appointment of Patrick F. Cua as Chief Executive Officer.
  • "Glytec is an early innovator for inpatient glycemic management SaaS and has built and maintained a reputation as the trusted partner for healthcare providers," said Cua.
  • I'm excited to grow the organization and scale its technology through this transformative time, not just for Glytec, but also for healthcare and the diabetes technology industry."
  • To learn more about Glytec and its insulin management software, visit https://glytecsystems.com/ .

The Government of Ecuador Approves Atico’s Concession Extension Until 2049

Retrieved on: 
Thursday, January 4, 2024

This new period of validity for the concession is extended until 2049.

Key Points: 
  • This new period of validity for the concession is extended until 2049.
  • The new term of the concession will begin from the date of registration in the Mining Registry under the Agency for Regulation and Control of Energy and Non-Renewable Natural Resources.
  • This decision by the Government of Ecuador creates better conditions to continue the investment plans in La Plata.
  • In a favorable scenario where additional time is needed, in 2048, the Company can apply for another 25 year extension.

NSPA awards COMLOG a contract for Patriot missiles

Retrieved on: 
Wednesday, January 3, 2024

GEM-T, the Patriot Advanced Capability 2 (PAC-2) missile interceptor enhanced for defeating tactical ballistic missiles, is a primary effector for the combat-proven Patriot air and missile defense system.

Key Points: 
  • GEM-T, the Patriot Advanced Capability 2 (PAC-2) missile interceptor enhanced for defeating tactical ballistic missiles, is a primary effector for the combat-proven Patriot air and missile defense system.
  • The world's battle-proven air and missile defense system, Patriot is relied upon by eight European nations, and Ukraine, for defense against cruise missiles, ballistic missiles, and enemy drones and aircraft.
  • The new production capacity for Patriot GEM-T missiles in Europe enhances security of supply and will contribute to the replenishment of Patriot air defense missile inventories.
  • COMLOG's main customer is the NSPA, which operates on behalf of the European Patriot user countries and the U.S. Army.

Five Big Questions (and Zero Predictions) for the U.S. State Privacy Landscape in 2024

Retrieved on: 
Tuesday, January 2, 2024

Entering 2024, the United States now stands alone as the sole G20 nation without a comprehensive, national framework governing the collection and use of personal data. With bipartisan efforts to enact federal privacy legislation once again languishing in Congress, state-level activity on privacy dramatically accelerated in 2023. As the dust from this year settles, we [?]

Key Points: 


Entering 2024, the United States now stands alone as the sole G20 nation without a comprehensive, national framework governing the collection and use of personal data. With bipartisan efforts to enact federal privacy legislation once again languishing in Congress, state-level activity on privacy dramatically accelerated in 2023. As the dust from this year settles, we [?]

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – OTLK

Retrieved on: 
Tuesday, January 2, 2024

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) and certain officers.

Key Points: 
  • NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) and certain officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Outlook is a late clinical-stage biopharmaceutical company that focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.